Skip to main content

Table 2 Treatment Related Adverse Events occurring in > 10% of subjects OR ≥ grade 3

From: Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies

Adverse events Grade 1–2 Grade 3 Grade 4
Fatigue 23 (65.7%) 1 (2.9%)  
Nausea 20 (57.1%)   
Anorexia 11 (31.4%)   
Vomiting 11 1  
Edema 10 (28.6%)   
Anemia 8 (22.9%) 1  
Diarrhea 8   
Rash 8 1  
Shortness of breath 7 (20%)   
Constipation 5 (14.3%)   
Thrombocytopenia 4 (11.4%)   
Fever   1  
Hypoglycemia   1